Rat brain glucose transporter-2, insulin receptor and glial expression are acute targets of intracerebroventricular streptozotocin: risk factors for sporadic Alzheimer's disease? by Knezović, Ana et al.
  
 
    
 
Središnja medicinska knjižnica 
 
 
 
Knezović A., Lončar A., Homolak J., Smailović U., Osmanović Barilar J., 
Ganoci L., Božina N., Riederer P., Šalković-Petrišić M. (2017) Rat brain 
glucose transporter-2, insulin receptor and glial expression are acute 
targets of intracerebroventricular streptozotocin: risk factors for 
sporadic Alzheimer's disease?  Journal of Neural Transmission, 124 
(6). pp. 695-708. ISSN 0300-9564 
 
http://www.springer.com/journal/702 
 
http://link.springer.com/journal/702 
 
The final publication is available at Springer via 
http://dx.doi.org/10.1007/s00702-017-1727-6 
 
 
http://medlib.mef.hr/2862 
 
 
 
University of Zagreb Medical School Repository 
http://medlib.mef.hr/ 
   
 
RAT BRAIN GLUCOSE TRANSPORTER-2, INSULIN RECEPTOR AND GLIAL 
EXPRESSION ARE ACUTE TARGETS OF INTRACEREBROVENTRICULAR 
STREPTOZOTOCIN: RISK FACTORS FOR SPORADIC ALZHEIMER’S DISEASE? 
 
Knezovic A1, Loncar A1,2, Homolak J1, Smailovic U1,3, Osmanovic Barilar J1, 
Ganoci L4, Bozina N1,4, Riederer P5, Salkovic-Petrisic M1* 
 
1 Department of Pharmacology and Croatian Institute for Brain Research, University 
of Zagreb School of Medicine, Zagreb, Croatia 
2   Department of Neurology, General Hospital Karlovac, Karlovac, Croatia 
3 Department of Neurobiology, Care Sciences and Society, Division of Clinical 
Geriatrics, Karolinska Institute, Stockholm, Sweden 
4 Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, 
Croatia 
5 Centre of Mental Health, Department of Psychiatry, Psychosomatics, and 
Psychotherapy, University Hospital of Würzburg, Würzburg, Germany 
 
 
 
 
 
 
 
 
 
*Corresponding author: Melita Salkovic-Petrisic 
e-mail address:  melitas@mef.hr 
Phone number:  +38514590219 
Postal address:  Department of Pharmacology 
    University of Zagreb School of Medicine  
    Salata 11 
    10 000 Zagreb 
    Croatia 
  
  
2 
 
ABSTRACT 
Accumulated evidence suggests that the insulin resistant brain state and cerebral 
glucose hypometabolism might be the cause, rather than the consequence, of the 
neurodegeneration found in a sporadic Alzheimer’s Disease (sAD). We have 
explored whether the insulin receptor (IR) and the glucose transporter-2 (GLUT2), 
used here as their markers, are the early targets of intracerebroventricularly (icv) 
administered streptozotocin (STZ) in a STZ-icv rat model of sAD, and whether their 
changes are associated with the STZ-induced neuroinflammation. The expression of 
IR, GLUT2 and glial fibrillary acidic protein (GFAP) was measured by 
immunofluorescence and Western blot analysis in the parietal (PC) and the temporal 
(TC) cortex, in the hippocampus (HPC) and the hypothalamus (HPT). One hour after 
the STZ-icv administration (1.5 mg/kg), the GFAP immunoreactivity was significantly 
increased in all four regions, thus indicating the wide spread neuroinflammation, 
pronounced in the PC and the HPC. Changes in the GLUT2 (increment) and the IR 
(decrement) expression were mild in the areas close to the site of the STZ 
injection/release but pronounced in the ependymal lining cells of the 3rd ventricle, 
thus indicating the possible metabolic implications. These results, together with the 
finding of the GLUT2-IR co-expression, and also the neuronal IR expression in PC, 
TC and HPC, indicate that the cerebral GLUT2 and IR should be further explored as 
the possible sAD etiopathogenic factors. It should be further clarified whether their 
alterations are the effect of a direct STZ-icv toxicity or they are triggered in a 
response to STZ-icv induced neuroinflammation.  
 
Keywords: streptozotocin, Alzheimer’s disease, glucose transporter 2, insulin 
receptor 
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INTRODUCTION 
 
Alzheimer’s disease (AD) is the most common type of dementia in the world today, 
however the precise etiology and pathogenesis of the predominanting sporadic form 
(sAD), still remain to be clarified. Recently accumulated evidence support the 
concept that the insulin resistant brain state (IRBS) and the cerebral glucose 
hypometabolism might be the pathological core of sAD (Chen and Zhong 2013; De 
Felice et al. 2014; Chen et al. 2014a; de la Monte and Tong 2014). IRBS is a 
condition molecularly characterized by the reduced response to insulin signaling 
downstream the insulin receptor (IR) - phosphatidylinositol -3 kinase (PI-3K) pathway 
in the brain. Considering the neurotrophic, neuroprotective and neuromodulatory role 
of brain insulin, IRBS leads to the neurodegeneration and cognitive impairment in an 
animal model of sAD (Lester-Coll et al. 2006; Agrawal et al. 2011; Barilar et al. 2015; 
Knezovic et al. 2015). IRBS was also found in sAD patients post-mortem (Frölich et 
al. 1998; Steen et al. 2005; Talbot et al. 2012; Yarchoan et al. 2014; Stanley et al. 
2016). It represents a brain-related metabolic syndrome, associated with the 
metabolic and oxidative stress and the neuroinflammation of the brain, which may or 
may not be accompanied by the alterations in the peripheral metabolic homeostasis, 
since diabetes type 2 (T2DM) increases the risk for AD (and vice versa). However, 
not all T2DM patients develop AD (and vice versa) and the AD is not necessarily 
associated with hyperglycemia (Blázquez et al. 2014; Talbot 2014). 
 
While IRBS can be detected only post-mortem, giving no clue on the time of its onset, 
the neuroimaging technology has enabled in vivo visualization of the impairment in 
the cerebral glucose metabolism of sAD patients (2-[18F]fluoro-2-deoxy-d-glucose 
PET /FDG-PET/ studies. This impairment was found especially in the parietotemporal 
and the frontal association cortices, and was pronounced in hippocampus, which has   
high glucose demands and insulin sensitivity (Mosconi 2005). Although still not well 
understood, the impairment of cerebral glucose uptake/metabolism in sAD appears to 
be the cause, rather than the consequence of neurodegeneration found in sAD, as it 
appears to precede cognitive dysfunction for many years. Two-year follow-up study 
of the cognitively normal individuals (aged 50-82 years) demonstrated that the 
maternal history of AD predisposed them to the baseline reductions in the brain 
glucose metabolism of  the AD-vulnerable brain regions, which significantly 
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progressed over the follow-up time, in comparison to those with maternal AD 
negative or paternal AD positive history (Mosconi et al. 2009). Furthermore, late 
middle aged cognitively normal subjects (50-65 years), who were homozygous for the 
e4 allele for apolipoprotein E and reported a family history of probable AD, had 
reduced glucose metabolism on PET images in the same regions of the brain as the 
patients with probable AD (Reiman et al. 1996). Although these findings do not 
directly prove the cerebral hypometabolism as the earliest event in AD, they are 
currently the earliest known measurable abnormality in the brain connected to AD 
(Cunnane et al. 2011).  
 
Specific nature of AD and a long presymptomatic phase do not allow the exploration 
of the precise onset of IRBS and the cerebral glucose hypometabolism as the 
possible etiopathogenic factors during the life-time of sAD patients, which is why the 
animal models of sAD are used to enlighten this problem. 
 
The non-transgenic rat model that has been proposed as a model of sAD is 
generated by intracerebroventricular administration of low-dosed streptozotocin (2-
deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; so called STZ-icv model (Hoyer 
1998; Lannert and Hoyer 1998). Indeed, STZ-icv application to rats induces 
progressive deficits in learning and memory (Mayer et al. 1990; Saxena et al. 2008; 
Knezovic et al. 2015) and neurochemical and neuropathological alterations in the 
brain that resemble those found in sAD patients (Salkovic-Petrisic and Hoyer 2007); 
decreased cholinergic transmission (Blokland and Jolles 1993; Agrawal et al. 2009; 
Biasibetti et al. 2017), oxidative stress (Sharma and Gupta 2001; Dias et al. 2014; 
Prakash et al. 2015) and neuroinflammation (Prickaerts et al. 1999; Kraska et al. 
2012; Biasibetti et al. 2017), tau hyperphosphorylation and early neurofibrillary 
changes (Deng et al. 2009; Barilar et al. 2015; Knezovic et al. 2015), and 
pathological accumulation of amyloid β 1-42 (Aβ1-42) in meningeal and cortical 
capillaries (Salkovic-Petrisic et al. 2006; Salkovic-Petrisic et al. 2011), neurons and 
eventually in primitive plaque-like formations (Knezovic et al. 2015). Most importantly, 
in addition to all these pathologies, the STZ-icv rat model generates IRBS (Lester-
Coll et al. 2006; Grünblatt et al. 2007; Agrawal et al. 2011; Barilar et al. 2015) and 
demonstrates reduction in cerebral glucose/energy metabolism (Plaschke and Hoyer 
1993; Hoyer et al. 1994; Hoyer and Lannert 2007). IRBS induced by STZ-icv 
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administration is characterized by the decrease in insulin receptor (IR) mRNA and 
protein expression and the IR signalling dysfunction downstream of the PI-3K 
pathway in particular brain regions, resulting in the increased activity of glycogen 
synthase kinase (GSK-3β) and the hyperphosphorylation of tau protein (Lester-Coll 
et al. 2006; Agrawal et al. 2011; Barilar et al. 2015). Reduction in cerebral glucose 
metabolism in the STZ-icv rat model has been found in 17 of 35 rat brain areas, 
particularly in the frontal, parietal, sensory motor, auditory and entorhinal cortex and 
in all hippocampal subfields (Duelli et al. 1994), while significant decreases in the 
activities of glycolytic key enzymes were found in the brain cortex and hippocampus 
(Plaschke and Hoyer 1993). 
 
STZ-icv mice model that shares the similar pathophysiology with STZ-icv rat model 
(cognitive deficits, IRBS, oxidative stress and neuroinflammation) has lately been 
introduced in a basic AD research (Chen et al. 2013; Li et al. 2016; Amiri et al. 2016). 
STZ-icv treatment of transgenic AD mice has been shown to exacerbate cognitive 
deficits as well as tau hyperphosphorylation and amyloid plaque formation (Plaschke 
et al. 2010) in addition to neuroinflammation (Chen et al. 2014b).  
 
There are three important facts, which indicate why more attention should be paid to 
the STZ-icv-induced generation of IRBS and the development of cerebral glucose 
hypometabolism, considered to be the possible sAD etiopathogenic markers. Firstly, 
the peripheral administration of STZ induces diabetes mellitus type I (T1DM) after a 
single high dose of this compound, or insulin resistance and diabetes mellitus type 2 
(T2DM) after its multiple low doses (Blondel and Portha 1989; Szkudelski 2001). It 
has been suggested that the diminished IR autophosphorylation and the kinase 
activity could provide a possible mechanism for the post-binding insulin resistance in 
diabetic rats, although it was not clear whether the diabetic metabolism rather than a 
toxic effect of STZ itself should account for this phenomenon (Kadowaki et al. 1984; 
Giorgino et al. 1992). Changes in IR autophosphorylation and tyrosine kinase activity 
have been found also in the brain of the STZ-icv rat model (Grünblatt et al. 2007), 
however it has been argued that the IR damage is caused directly by the icv 
injections of STZ (Grieb 2016). Secondly, STZ enters the cell as a selective substrate 
for the glucose transporter 2 (GLUT2), which is highly concentrated at the membrane 
of pancreatic β cells (Szkudelski 2001) but to a lesser extent is present also in the 
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brain (Brant et al. 1993; Arluison et al. 2004a; Arluison et al. 2004b). Not only has 
STZ been a selective substrate for the GLUT2 (and not for the other GLUTs), but in 
vitro and in vivo studies have also demonstrated that GLUT2 itself is a key target 
molecule for STZ, which reduces GLUT2 protein expression and mRNA in a 
concentration-dependent manner (Wang and Gleichmann 1995; Wang and 
Gleichmann 1998; Gai et al. 2004). GLUT2 in the brain is involved in the glucose 
sensing and transportation, and the glucose transportation and intracellular oxidative 
catabolism are the two main processes which regulate cerebral glucose metabolism 
(Maekawa et al. 2000; Chen and Zhong 2013). Decreased intracellular oxidative 
catabolism of glucose has been demonstrated in the brain of STZ-icv rats (Plaschke 
and Hoyer 1993; Hoyer et al. 1994), but data on the alterations of the cerebral 
GLUT2 levels in this model are still lacking. Thirdly, the mechanism(s) of intracellular 
STZ toxicity in the pancreatic β cells is well known, and, together with the DNA 
damage, the decrement in the ATP level and the inhibition of O-GlcNAc-selective N-
acetyl-β-D-glucosaminidase (O-GlcNAcase), it involves also the induction of 
nitrosative/oxidative stress with the generation of nitric oxide (NO), free radicals and 
hydrogen peroxide (Szkudelski 2001; Konrad et al. 2001). However, the mechanism 
of STZ toxicity is far less clear in the brain. Oxidative stress and neuroinflammation, 
as well as the mitochondrial abnormalities, are quite prominent pathological 
alterations in the brain of both, AD patients and STZ-icv rats (Prickaerts et al. 1999; 
Sharma and Gupta 2001; Kraska et al. 2012; Correia et al. 2013) however, it is not 
clear whether they precede IRBS and cerebral glucose metabolism dysfunction. 
 
We have investigated whether IR and GLUT2 in the rat brain are the early targets of 
STZ following its icv administration, and if their changes are associated with the 
neuroinflammation. Our research was primarily focused on the brain regions involved 
in the cognition, i.e. parietotemporal cortex and hippocampus, but after the 
unexpected findings of the intensive immunoreactive neuroinflammatory signal in the 
hypothalamic region of the STZ-icv group, the histology analysis of the hypothalamus 
was also performed. 
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MATERIAL AND METHODS 
 
Materials 
STZ, protease inhibitor cocktail, paraformaldehyde, monoclonal mouse anti-β-actin 
and monoclonal mouse anti-GFAP antibodies, fluoroshield, and normal goat serum 
were purchased from Sigma-Aldrich (St. Louis, Missouri, USA). The anti-GLUT2 
(rabbit polyclonal antibody) secondary antibody was purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). Secondary antibodies HRP-linked goat anti-
mouse and anti-rabbit were purchased from Cell signalling (Beverly, MA, USA). 
Mouse monoclonal anti-IR antibody (β-subunit) was purchased from Merck Millipore 
(Billerica, MA, USA). Secondary antibodies Alexa Fluor 488 goat anti-rabbit and 555 
goat anti-mouse were purchased from Invitrogen (Carlsbad, CA, USA). The 
chemiluminescent Western blot detection kit (SuperSignal West Femto 
Chemiluminescent Substrate) was from Thermo Scientific (Rockford, IL, USA). 
 
Animals 
Male Wistar rats (three-month-old) weighing 280-350 g (Department of 
Pharmacology, University of Zagreb School of Medicine) were used in the 
experiment. The rats were kept 2-3 per cage in a room with a 12 h light/12 h dark 
cycle (lights on 7 a.m. - 7 p.m.), and the room temperature and humidity set in the 
range of 21-23°C and 40-70%, respectively. All animals were kept on standardized 
food pellets and water ad libitum.  
 
Drug treatments 
Rats were given general anesthesia (thiopental 50 mg/kg; 5 mg/kg diazepam), 
followed by a single icv injection of STZ (1.5 mg/kg, dissolved in vehicle: 0.05 M 
citrate buffer, pH 4.5, split in two equal dose given bilaterally in a volume of 2 
l/ventricle), according to the procedure first described by Noble et al. (1967) and 
used in our previous experiments (Lackovic and Salkovic 1990; Grünblatt et al. 2007; 
Salkovic-Petrisic et al. 2013; Barilar et al. 2015; Knezovic et al. 2015). Control (CTR) 
animals were given an equal volume of vehicle by the same procedure. There were 8 
animals per each group (CTR and STZ), all together 16 animals.  
 
Tissue preparation   
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Animals were sacrificed in deep anaesthesia (thiopental 50 mg/kg; 5 mg/kg 
diazepam) 1 hour following the treatment. Six out of 8 animals per group were 
decapitated after which brains were quickly removed, hippocampus (HPC), temporal 
cortex (TC) and parietal cortex (PC) were dissected out and frozen in liquid nitrogen 
(Paxinos and Watson 2005). Since we were primarily focused to explore the regions 
involved in cognition, hypothalamus (HPT) has not been dissected out for Western 
blot analysis. Brain tissue samples for Western blot analysis were thawed and 
homogenized with three volumes of lysis buffer containing 10mM HEPES, 1mM 
EDTA, 100 mM KCl, 1% Triton X-100, pH 7,5, and a protease inhibitor cocktail 
(1:100) and the homogenates were centrifuged at 12000 rpm for 10 min at 4°C and 
the supernatant were frozen and stored at -80°C. Protein concentration was 
measured by Lowry protein assay. Remaining 2 animals per group were perfused 
with 4% paraformaldehyde, pH 7.4. Brains were removed and cryoprotected with 
sucrose (through series of sucrose 15% and 30%) and stored at -80°C.  
 
Immunofluorescence 
Brains were cut on cryostat (35 µm), and coronal sections were used for the free-
floating immunofluorescence method. The sections were first washed with PBST 
(PBS buffer with 0.25% Triton X-100) and then blocked in 10% NGS in PBST. 
Section were then incubated overnight at 4°C with anti-GFAP antibody (1:500) and 
with both anti-IR and anti-GLUT2 antibodies (1:250) diluted in 1% NGS in PBST. On 
the second day, sections were washed with PBST and incubated with appropriate 
fluorescent secondary antibodies for 2h at RT. After washing in PBST, sections were 
mounted on slides with fluoroshield mounting medium. Slides were examined and 
visualized by microscope Olympus BX51 and CellSense Dimension software, and the 
co-expression was visualized by EMCCD microscopy camera. 
 
Western blot analysis  
Equal amounts of total protein in HPC, TC, and PC (35 µg per sample) were 
separated by sodium dodecyl sulphate-polyacrylamide (SDS) gel electrophoresis 
using 9% polyacrylamide gels and transferred to nitrocellulose membranes. The 
nitrocellulose membranes were blocked by incubation for 1 h at RT in 5% non-fat milk 
added to low-salt washing buffer (LSWB) containing 10mM Tris, 150mM NaCl, pH 
7.5, and 0.5% Tween 20. Blocked blots were incubated with primary anti-GLUT2 
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(1:1000) and anti-IR (1:2000) antibodies overnight at 4°C. After incubation, the 
membranes were washed three times with LSWB and incubated for 1 h at RT with 
appropriate secondary antibody solution (anti-mouse and anti-rabbit IgG, 1:2000). 
After washing three times in LSWB signals were captured and visualized with 
MicroChemi video camera (DNR Bio-Imaging Systems) using chemiluminescence 
reagent. The membranes were washed three times with LSWB, blocked in the same 
way and incubated with loading control, anti-β-actin (1:2000) overnight, at 4°C. After 
incubation, the membranes were washed and incubated for 1 h at RT with secondary 
antibody solution (anti-mouse 1:2000), washed in LSWB and signals were captured 
and visualized with MicroChemi video camera using chemiluminescence reagent. 
The membranes were analysed with ImageJ software. 
Since HPT has become a region of interest only after a marked neuroinflammation 
observed by immunofluorescence staining, and due to has not been dissected out for 
Western blot analysis at the time of sacrificing, GLUT2 and IR expression in HPT 
could have been explored only by immunofluorescence and not by Western blot. 
 
Ethics 
Animal procedures, carried out at the University of Zagreb Medical School (Zagreb, 
Croatia), were in compliance with current institutional, national (The Animal 
Protection Act, NN135/2006; NN 47/2011), and international (Directive 2010/63/EU) 
guidelines governing the use of experimental animals. The experiments were 
approved by the national regulatory body responsible for issuing ethical approval, 
Croatian Ministry of Agriculture and Ethical Committee, Medical School of Zagreb. 
 
Statistics 
Quantitative analysis of the GFAP positive signal was performed based on the 
measured area with the background subtraction done to reduce the background 
noise by means of CellSense Dimension imaging software. Data were expressed as 
mean ± SD and statistically analysed by Mann-Whitney U test (p < 0.05) using 
GraphPad Prism 5 statistical software.  
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RESULTS 
 
GFAP expression in the brain 
Immunoreactivity of GFAP was detected by the immunofluorescence assay and a 
positive signal was found in the regions of interest, cortex (TC, PC) and hippocampus 
(HPC), but was unexpectedly pronounced also in HPT (Fig .1). In the control group 
HPC was found to contain intensely stained, clearly stratified GFAP-staining, with 
substantially more immunoreactivity occurring in the dentate gyrus, while PC, TC, 
and HPT showed evenly distributed astrocytes (Fig 1A represents layer IV-V). In the 
STZ-icv treated animals the signal was increased in all four brain regions indicating a 
global neuroinflammatory response one hour after the STZ-icv treatment (Fig 1A). 
The quantification of the GFAP signal revealed that the increment in the STZ-icv 
group was significant in all four regions in comparison to the controls (p<0.05) (Fig. 
1B). However, it was pronounced more in the PC (+109%) and the HPC (+94%) than 
in the TC (+70%) and the HPT (+63%) (Fig 1B). Such a regional distribution of the 
GFAP signal intensity may indicate the time- and concentration-dependent effect of 
STZ; i.e. the highest concentration close to the site of the needle breakthrough in PC 
and release of STZ from the needle in the vicinity of HPC, followed by 
spreading/diffusing of STZ diluted by CSF to more distal regions, HPT and TC (Fig 
1B, C). The GFAP immunoreactivity in the cortical and the hippocampal region 
across and near the site of a needle injection is presented in the Supplementary 
material (Suppl 1). 
 
IR and GLUT2 expression in the brain 
 
Cortex and hippocampus  
 
Positive IR immunoreactivity (red signal) was found in all brain regions of interest 
both in the control and the STZ-icv group (Fig 2-4). In the PC, TC and HPC, the 
signal was predominately on the neuronal membranes, as shown by IR – NeuN co-
localization presented in the Supplementary material (Suppl 3). Mild decrement (-
13%; p<0.05) in the IR protein expression, quantified by Western blot analysis, was 
found in the PC of STZ-icv group (Fig. 5), while no change in the IR level could have 
been quantified in the TC and HPC (Fig. 5).  
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Positive GLUT2 immunoreactivity (green signal) in the control and the STZ-icv group 
was also found in the PC, TC and HPC although less spread than the IR 
immunoreactivity (Fig. 2-4). Statistically significant difference in the GLUT2 protein 
level between the groups was found by Western blot analysis only in the HPC of the  
STZ-icv group which demonstrated +33% increment in comparison to the control 
group (p<0.05) (Fig. 5). This increment can be seen on the immunofluorescence 
photomicrographs as more intense green signal (Fig. 4). No change in the GLUT2 
signal/protein expression was observed in the two cortical regions (Fig. 2-5).  
 
Merging of the photomicrographs which detected two different immunofluorescent 
signals (red/IR and green/GLUT2) in the same tissue sections demonstrated co-
localization of IR and GLUT2 in the particular cells of the PC, TC and HPC, seen as 
the yellow/orange merged signal (Fig. 2-4). 
 
Hypothalamus 
 
At the level of the hypothalamus, IR (red signal) and GLUT2 (green signal) 
immunoreactivity was found only in the ependymal lining cells of the 3rd ventricle (Fig. 
6). The control group demonstrated only the IR immunoreactivity in these cells with 
no visible specific GLUT2 signal (Fig. 6A). In the STZ-icv group, the IR 
immunoreactivity in the ependymal cells was clearly reduced both in intensity and 
spread while the appearance of a strong signal of the GLUT2 immunoreactivity was 
detected in this hypothalamic area (Fig. 6A). Double immunofluorescence revealed 
co-expression of the GLUT2 and IR signal in the long ependymal cells, as observed 
by confocal microscope (Fig. 6B).  
 
DISCUSSION 
 
We have used the STZ-icv treated rats as a non-transgenic sAD model (Hoyer 1998; 
Lannert and Hoyer 1998) to explore the onset of alterations in IR and GLUT2 levels 
as the markers of IRBS and the cerebral glucose hypometabolism. Both are 
proposed to be possible etiopathogenic factors of sAD (Chen and Zhong 2013; De 
Felice et al. 2014; Chen et al. 2014a; de la Monte and Tong 2014). In the brain, STZ 
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toxicity has been associated with the neuroinflammation, reported so far to be 
present ≥1 week after STZ-icv administration (Salkovic-Petrisic and Hoyer 2007). 
Both, the GLUT2 alteration and the neuroinflammation have been detected in our 
experiments but the latter one appears to be more spread 1 hour after a single 1.5 
mg/kg STZ-icv dose. 
 
Neuroinflammation is a prominent and early feature of AD, which involves the 
activation of glial cells represented by a highly heterogeneous population of mostly 
microglia and astrocytes (Ransohoff, 2016). It is estimated that the astrocytes 
represent 30-50% of human neural cells (Lent et al, 2012) and are the most 
abundant type of glial cells in the brain (Steardo et al., 2015). While the role of 
microglia in the neuroinflammatory response to AD has been extensively explored 
(Heppner et al, 2015), recent data indicate that the astrocyte-mediated inflammatory 
processes also contribute to the neurodegeneration in AD or may even be one of the 
major hallmarks of this disease (Garwood et al., 2016; Verkhratsky et al., 2010). 
Astrocytosis was proved to be an early phenomenon in AD progression in patients 
with MCI and AD subjected to multitracer PET analysis (Carter et al., 2012). 
Astrocytosis is typically characterised by the increased expression of the astrocyte 
marker GFAP (Garwood et al., 2016). Human studies showed that the astrocyte 
hypertrophic response, characterized by the GFAP expression increases early in 
relation to the development of the AD neuropathology (Simpson et al., 2010). In our 
experiments, the STZ-icv treatment induced the extensive expression of 
neuroinflammation as early as 1 hour after the injection, visualized by both, the 
increased density and the intensity of GFAP-positive signal, especially in the parietal 
cortex and hippocampus, but also in the temporal cortex and the hypothalamic 
region. Neuroinflammation is often found in parallel with the oxidative stress, but 
some data also show that these two appears to be the separate events, which work 
in concert to modulate the development of the AD-like pathology, as shown in the 
transgenic mice AD model (Yao et al. 2004). In the neuroinflammatory process, 
astrocytes and neurons can produce/release inflammatory mediators, including 
reactive oxygen and nitrogen species (Agostinho et al. 2010). Additionally, oxidative 
stress which is implicated in the AD pathogenesis (Gsell et al. 1996; Agostinho et al. 
2010), can trigger the overexpression of inducible nitric oxide synthase leading to an 
increased NO production (Agostinho et al. 2010). In line with that, the experiments of 
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Rajasekar et al. (2014) showed dose-dependent cytotoxicity of STZ in the rat 
astrocytoma cell line during the 24-hour incubation time, and the induction of NO 
release, as well as the dose- dependent generation of reactive oxidative species, the 
increased formation of malondialdehyde and the glutathione deficit. STZ-induced 
release of NO in the rat pancreatic β cells was seen already 2 hours after the 
treatment (Wada and Yagihashi 2004). NO was found to be liberated in β cells only 
when STZ had been metabolized inside the cell (Kröncke et al. 1995). The 
pharmacokinetics of STZ have been explored so far in rats after the parenteral 
administration, showing that 30% of the compound is eliminated within the first hour 
in the form of the degrading products and partly as the unchanged molecule (Lee et 
al. 1993), while in cell culture its biological half-life was shown to be approximately 19 
minutes (Jensen et al. 1977).  Some of its cleavage/degradation products, which 
chemical structure has not been clearly defined yet, were shown to have some 
biologic, although not diabetic, activity (Lee et al. 1993), and a capability of crossing 
cell membranes (Goud et al. 2015). There are no data on the STZ pharmacokinetics 
following its icv administration. However, the occurrence of the direct STZ effects 
and/or the effects of some of its cleavage/degradation products with similar 
characteristics to those found after the parenteral STZ administration cannot be 
excluded in such a short period as 1 hour after the STZ-icv injection. 
 
Previous research suggested that the damage caused by the administration of STZ 
into the lateral ventricles is restricted to the brain areas near to the site of injection 
(Terwel et al. 1995; Shoham et al. 2003). In our experiment, the neuroinflammation 
induced in the vicinity of the site where STZ was released (hippocampus) was indeed 
highly pronounced compared to the one found after the citrate buffer injection (Suppl 
1). However, our results also showed that after 1 hour, the neuroinflammation was 
expressed not only in the vicinity of the STZ injection and downstream the 
hypothalamic areas close to the cerebrospinal fluid (CSF) exposure, but also in the 
temporal cortex which falls in neither of the categories. The possibility that a single 
STZ dose injected into the lateral ventricles is capable of inducing metabolic and 
cytoarchitectonic responses in such a distant location as temporal cortex through a 
direct damage in that region, has been argued by Grieb (2016).   
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A possible interpretation of these findings could be that the extent and the dynamics 
of brain damage and the neuro/histopathological changes induced by the STZ-icv 
administration might depend on the amount of STZ injected as a single or cumulative 
dose. Kraska and coworkers (2012) followed up the progression of cerebral lesions 
and neuroinflammation induced in rats by the icv administration of 1 and 3 mg/kg of 
STZ respectively for the period of one week and up to three months after the 
treatment. They showed that high STZ-icv dose induced severe and acute 
neurodegenerative lesions restricted to the site of injection associated with the 
severe neuroinflammation, while the changes were less severe but more widespread 
and progressive at a low dose. These findings are in line with other toxic effects of 
STZ reported to be induced in a dose- (Rajasekar et al. 2014) and time-dependent 
manner (Santos et al. 2012), both found to affect the dynamics of cognitive deficits in 
a 9-month follow-up of STZ-icv rat model (Knezovic et al. 2015). In this respect, it is 
difficult to interpret neuroinflammation as well as the changes in the IR/GLUT2 
expression found 1 hour after a single icv injection of 1.5 mg/kg STZ dose, in 
comparison with the literature data where either higher STZ-icv dose (3 mg/kg) was 
used to generate a model and/or the effects were observed after a period of weeks or 
months (as reviewed by Salkovic-Petrisic and Hoyer, 2007). 
 
The neuroinflammation is either expressed (with or without of the possible differences 
in the intensity and/or distribution), or there are no signs of neuroinflammation. 
Contrary to that, the expression of cerebral IR/GLUT2 might additionally be 
susceptible to fluctuations in the metabolic status in the brain caused by STZ-icv and 
consequently be increased, decreased or unchanged. Our results provide the insight 
into the earliest changes in the expression of IR and GLUT2 in the rat brain following 
the STZ-icv injection. The expression of these two proteins show pronounced 
regional specificity. The changes are present in areas close to the site of STZ release 
from a needle (hippocampus /GLUT2) and downstream the CSF flow (the ependymal 
lining cells of the 3rd ventricle/GLUT2, IR), with either mild (IR) or no change (GLUT2) 
in the cortical regions. However, the observed changes were of the opposite 
direction, seen as increased GLUT2, and decreased IR expression.  
 
Although the changes of the cerebral GLUT2 protein expression found 1 hour after 
the STZ-icv treatment appear to be opposite to the STZ-induced decrement in 
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GLUT2 expression in pancreatic β cells (Wang and Gleichmann 1995; Wang and 
Gleichmann 1998; Gai et al. 2004), it does not necessarily indicate that the 
mechanism of the STZ action is different after its peripheral and central 
administration. One speculative explanation could be that as early as 1 hour post-
treatment, the neuroinflammation induced by STZ-icv treatment generates a state 
with the increased metabolic need which cell is trying to compensate by increasing 
the influx of glucose, and this may be accomplished by the increased membrane 
expression of GLUT2 (Kalsbeek et al. 2016). The interplay of the neuroinflammation 
and the oxidative stress as two separate, yet closely connected events, might have 
an important role here. Susceptibility to oxidative stress in the brain is regionally 
specific with some regions being more sensitive than the others, hippocampus in 
particular (Austin et al. 2015). This might provide a possible explanation why the 
changes in GLUT2/IR expression were not found in all investigated regions in spite of 
the expression of the neuroinflammation. The cell/GLUT2 responsiveness and the 
adjustability to the metabolic needs might be possible in this early acute phase, and 
at this low STZ-icv dose, but is probably lost in the course of time. This is in line with 
the findings in pancreatic β cells, where the STZ-induced decrement in the GLUT2 
protein expression was time- and dose-dependent and first noticed 1 day after the 
third STZ injection (Wang and Gleichmann 1995; Wang and Gleichmann 1998; Gai et 
al. 2004). This hypothesis is supported by our preliminary research of GLUT2 protein 
and mRNA expression in the brain of the rat STZ-icv model induced by two STZ-icv 
injections (2x 1.5 mg/kg) and measured 1 month after the treatment (Suppl 2). These 
supplementary results demonstrate that the 2xfold higher STZ-icv dose and much 
longer post-treatment period than here are associated with the decreased expression 
of GLUT2 protein in the parietal and temporal cortex and the decreased GLUT2 
mRNA expression in the parietal cortex. Decreased GLUT2 mRNA expression found 
in our supplementary experiments is in line with the similar STZ effect in the 
pancreatic β cells (Wang and Gleichmann 1998). Therefore, GLUT2 in the brain also 
appears to be the target of STZ administered into the lateral ventricles, thus one may 
speculate that, similarly to what happens at the periphery, the appearance of this 
effect in the brain is STZ-icv dose- and time-dependent.  
 
GLUT2 is a bidirectional high-capacity glucose transporter which has been found 
throughout the rat brain mainly in the astrocytes but to a lesser extent also in the 
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neurons (Arluison et al. 2004a; Arluison et al. 2004b). The nerve cell bodies clearly 
immunostained for GLUT2 seem to be scarce, whereas the periphery of the 
numerous nerve cells is labelled for this transporter (Arluison et al. 2004b). The 
results presented here clearly show the GLUT2 signal in the some NeuN-positive 
neuronal cells in the parietotemporal cortex and hippocampus (Suppl 3). Additionally, 
our results also indicate the co-expression of GLUT2 and IR, observed in the regions 
investigated and particularly in the ependymal lining cells of the 3rd ventricle. Such a 
co-expression seems to be present in the skeletal muscles and liver (Rathinam and 
Pari 2016), however this is the first report of its presence in the rat brain. This finding 
may support the hypothesis that IR and its signalling pathway could be affected by 
STZ from the intracellular side, and not via the extracellular interaction, as argued by 
Grieb (2016). Also, it may not be excluded that from the intracellular side IR is the 
target of some biologically active degradation products of STZ, or STZ-induced 
oxidative stress markers. Therefore, changes in IR might be a consequence of its co-
expression with the direct target of STZ (GLUT2) in the same cell. On the other hand, 
it cannot be excluded that IR expression is influenced by the alteration in the 
intracellular metabolic status, induced by increased GLUT2 expression as a response 
to neuroinflammation. The type of possible GLUT2-IR interaction needs to be further 
explored, since our results indicate that there might be an inverse correlation 
between the expression of GLUT2 and IR protein, at least in this early phase. 
However, in contrast to our preliminary findings (Suppl 2) of GLUT2 change in the 
opposite direction in the course of time (increment after 1 hour and decrement after 1 
month), the expression of IR protein is uniformly decreased in both, the early and the 
late post-treatment periods, as corroborated by our results and a research of the 
other groups (Agrawal et al. 2011; Liu et al. 2013; Barilar et al. 2015). This may allow 
speculation that at low STZ dose, considering the GLUT2-IR co-expression, IR itself 
might be more sensitive to STZ-induced intracellular irreversible toxicity than GLUT2. 
 
In line with the literature data that GLUT2 in the hypothalamus is expressed mainly in 
the astrocytes and the tanycytes (Leloup et al. 2016), our experiments show highly 
increased GLUT2-positive signal particularly in the ependymal lining cells of the 3rd 
ventricle. According to the elongated cell shape, these cells seem to be tanycytes, 
the main glial cells present specifically at this location (García et al. 2003). 
Modulation of the hypothalamic GLUT2 expression has been shown to alter glucose 
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sensitivity and physiological responses such as the nervous control of insulin or 
glucagon secretion and food intake (Leloup et al. 2016). Our results indicate that in 
the acute phase, this region is strongly affected by STZ-icv treatment in regard to 
neuroinflammation, and GLUT2/IR expression which might have important 
implications for the regulation of metabolic homeostasis. Although blood glucose 
levels have been generally found unaltered in STZ-icv rat model, as reviewed 
elsewhere (Salkovic-Petrisic and Hoyer 2007), some variations in plasma insulin level 
have been observed in our preliminary subacute experiments (unpublished data). 
 
Conclusion 
The administration of a single low STZ dose into the lateral ventricles of the adult rats 
induces wide spread neuroinflammation in the cortical, the hippocampal and the 
hypothalamic regions and more regional specific alterations in the GLUT2 and IR 
protein expression, which was observed as early as 1 hour after the treatment. The 
expression of both GLUT2 and IR was altered in areas close to the site of STZ 
release from a needle (hippocampus) and downstream the CSF flow (the ependymal 
lining cells of the 3rd ventricle) with mild or no changes observed in the 
parietotemporal cortex. Considering the first evidence of GLUT2 – IR co-expression 
in the rat brain presented here, it cannot be excluded that IR and its signalling 
pathway could be affected by STZ (and/or some biologically active degradation 
products of STZ, or STZ-induced oxidative stress markers) from the intracellular side, 
and not via a direct extracellular interaction. Alterations of GLUT2 and IR, as well as 
their co-expression in the ependymal lining cells of the 3rd ventricle, should be further 
explored having in mind that modulation of hypothalamic GLUT2 expression affects 
the regulation of metabolic homeostasis at the periphery. Cerebral GLUT2 seems to 
be the target molecule of STZ following its icv administration, however further 
research is needed to clarify whether the early GLUT2 alterations might be also 
induced in a response to the neuroinflammation-induced metabolic needs.  
 
The findings of such early changes in GLUT2/IR expression and the development of 
neuroinflammation using the model considered to be a valuable model for sAD, might 
contribute to elucidate the sAD etiopathogenesis. Recent clinical study has revealed 
that the brain inflammation is likely to occur already at the preclinical stage of AD in 
MCI patients, and can be detected in vivo in the CSF as the increased level of 
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lymphocytes and pro-inflammatory cytokines IL6 and IL17 (Blum-Degen et al. 1995; 
Monson et al. 2014). Such an early appearance of brain inflammation in patients with 
preclinical AD might correspond with the neuroinflammation found here in the early 
phase of the STZ-icv rat model when AD-like pathological hallmarks, the early 
neurofibrillary changes, and the Aβ1-42 accumulation, have not appeared yet 
(Knezovic et al. 2015). GLUT2 expression in the brain has been poorly explored in 
sAD patients; post-mortem analysis showed increased GLUT2 level in the frontal 
cortex which disappeared after being normalized by GFAP level (Liu et al. 2008), and 
decreased GLUT2 mRNA in the cholinergic basal forebrain galanin-sensitive neurons 
(Counts et al. 2009). Although these clinical data seem to be inconclusive, they 
indicate that the alterations in GLUT2 in the brain might play a role in sAD 
pathophysiology and should be further explored, particularly regarding the possible 
co-expression with IR and the evidence of IRBS in sAD patients (Talbot et al. 2012). 
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Fig 1.  Immunoreactivity of the glial fibrillary acidic protein expression in the 
brain of streptozotocin-treated rats visualized by immunofluorescence. Animals 
were euthanized 1 hour after intracerebroventricular (icv) treatment with 
streptozotocin (STZ) (1.5 mg/kg) or vehicle (CTR). Slides with brain sections (35 µm 
thick slices) were subjected to immunofluorescence staining with the glucose 
transporter-2 (GLUT2) and the insulin receptor (IR) antibodies. Representative 
photomicrographs (the same exposition used for STZ and CTR slides in the same 
region) show the positive glial fibrillary acidic protein (GFAP) expression (red signal) 
detected one hour after icv injection in hippocampus (HPC), hypothalamus (HPT), 
parietal (PC) and temporal (TC) cortices (both in the cortical layer IV-V) (A). 
Quantitative analysis of the positive GFAP signal was performed by means of 
CellSense Dimension imaging software. Six sections per brain of each animal were 
analysed and the mean ± SEM value of the group was presented as a bar in a 
relative comparison to the area-matched respective control (B). Investigated regions 
are marked at the brain map, with a notification that PC and TC have not been at the 
same interaural and/or Bregma level (C). Statistical analysis was done by Mann-
Whitney U test (*p<0.05 compared to the control). Scale bar = 200 μm (HPC and 
HPT); 100 μm (PC and TC). Hippocampus - Dentate gyrus: P=polymorphic layer, 
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G=granular layer, M=molecular layer; Hypothalamus – 3v=3rd ventricle, 
DMH=dorsomedial hypothalamic nucleus 
 
 
Fig 2. Immunofluorescence staining of insulin receptor and glucose 
transporter-2 in the parietal cortex of the streptozotocin-treated rats. Animals 
were euthanized 1 hour after the intracerebroventricular (icv) treatment with 
streptozotocin (STZ) (1.5 mg/kg) or vehicle (CTR). Slides with brain sections (35 µm 
thick slices) were subjected to double immunofluorescence staining with the glucose 
transporter-2 (GLUT2) and the insulin receptor (IR) antibodies. Representative 
photomicrographs show the positive GLUT2 and IR signal in the parietal cortex 
(layers IV-V) seen as a green and red staining, respectively, detected one hour 
following the treatment. Single cells with a positive signal are indicated by the white 
arrowheads. The signal was then merged by CellSence Dimension software, and 
representative cells with co-expression of IR and GLUT2 (IR+GLUT2) indicated by 
the white arrows. Scale bar = 50 μm. 
 
  
30 
 
 
Fig 3. Immunofluorescence staining of insulin receptor and glucose 
transporter-2 in the temporal cortex of the streptozotocin-treated rats. Animals 
were euthanized 1 hour after the intracerebroventricular (icv) treatment with 
streptozotocin (STZ) (1.5 mg/kg) or vehicle (CTR). Slides with brain sections (35 µm 
thick slices) were subjected to double immunofluorescence staining with glucose 
transporter-2 (GLUT2) and the insulin receptor (IR) antibodies. Representative 
photomicrographs show the positive GLUT2 and IR signal in the temporal cortex 
(layers IV-V) seen as a green and red staining, respectively, detected one hour 
following the treatment. Single cells with a positive signal are indicated by the white 
arrowheads. The signal was then merged by CellSence Dimension software, and 
representative cells with co-expression of IR and GLUT2 (IR+GLUT2) indicated by 
the white arrows. Scale bar = 50 μm. 
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Fig 4. Immunofluorescence staining of insulin receptor and glucose 
transporter-2 in the hippocampus of the streptozotocin treated rats. Animals 
were euthanized 1 hour after the intracerebroventricular (icv) treatment with 
streptozotocin (STZ) (1.5 mg/kg) or vehicle (CTR). Slides with brain sections (35 µm 
thick slices) were subjected to double immunofluorescence staining with the glucose 
transporter-2 (GLUT2) and the insulin receptor (IR) antibodies. Representative 
photomicrographs show a positive GLUT2 and IR signal in the polymorphic layer of 
dentate gyrus seen as a green and red staining, respectively, detected one hour 
following the treatment. Single cells with a positive signal are indicated by the white 
arrowheads. The signal was then merged by CellSence Dimension software, and 
representative cells with co-expression of IR and GLUT2 (IR+GLUT2) indicated by 
the white arrows. Scale bar = 50 μm. 
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Fig 5. Glucose transporter-2 and insulin receptor protein expression in the 
hippocampus and the cerebral cortices (parietal and temporal) of the 
streptozotocin-intracerebroventricularly treated rats. Animals were euthanized 1 
hour after the intracerebroventricular (icv) treatment with streptozotocin (STZ-icv) (1.5 
mg/kg) or vehicle (CTR). Glucose transporter-2 (GLUT2) and insulin receptor (IR) 
protein expressions in the parietal (PC) and temporal (TC) cortex and the 
hippocampus (HPC) were measured by Western blot analysis with the representative 
blots being presented. Anti-β-actin was used as a loading control. Each bar 
(mean±SEM) represents relative ratio of signal intensity expressed by arbitrary units 
(au) for CTR and STZ. *p<0.05 vs CTR by Mann Whitney U test. 
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Fig 6. The effect of intracerebroventricular treatment of streptozotocin on the 
expression of glucose transporter-2 and insulin receptor in the rat 
hypothalamus. Animals were euthanized 1 hour after the intracerebroventricular 
(icv) treatment with streptozotocin (STZ) (1.5 mg/kg) or vehicle (CTR). Slides with 
brain sections (35 µm thick slices) were sub ected to immunofluorescence staining 
with the glucose transporter-2 (GLUT2) and the insulin receptor (IR) antibodies.  
Representative photomicrographs of the hypothalamic region at the level of 
dorsomedial hypothalamic nucleus show a positive GLUT2 and IR signal in the cells 
of ependymal lining of the 3rd ventricle seen as a green and red staining, respectively. 
Single cells with a positive signal are indicated by the white arrowheads. The signal 
was then merged by CellSence Dimension software, and representative cells with co-
expression of IR and GLUT2 (IR+GLUT2) indicated by the white arrows.  (A). 
IR+GLUT2 co-expression (indicated by the white arrows) in these cells was further 
visualized by confocal microscope (B). Scale bar = 50 µm and 10 µm for confocal 
microscope photomicrographs. 
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